Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 24;11(1):70.
doi: 10.3390/jcm11010070.

Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis

Steven H Rauchman  1 , Sherri G Mendelson  2 , Courtney Rauchman  1 , Lora J Kasselman  3 , Aaron Pinkhasov  3 , Allison B Reiss  3
Affiliations

Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis

Steven H Rauchman et al. J Clin Med. .

Abstract

SARS-CoV-2 continues to have devastating consequences worldwide. Though vaccinations have helped reduce spread, new strains still pose a threat. Therefore, it is imperative to identify treatments that prevent severe COVID-19 infection. Recently, acute use of SSRI antidepressants in COVID+ patients was shown to reduce symptom severity. The aim of this retrospective observational study was to determine whether COVID+ patients already on SSRIs upon hospital admission had reduced mortality compared to COVID+ patients not on chronic SSRI treatment. Electronic medical records of 9044 patients with laboratory-confirmed COVID-19 from six hospitals were queried for demographic and clinical information. Using R, a logistic regression model was run with mortality as the outcome and SSRI status as the exposure. In this sample, no patients admitted on SSRIs had them discontinued. There was no significant difference in the odds of dying between COVID+ patients on chronic SSRIs vs. those not taking SSRIs, after controlling for age category, gender, and race. This study shows the utility of large clinical databases in determining what commonly prescribed drugs might be useful in treating COVID-19. During pandemics due to novel infectious agents, it is critical to evaluate safety and efficacy of drugs that might be repurposed for treatment.

Keywords: COVID-19; SSRI; antidepressant; clinical presentation; disease severity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of retrospective cohort study of COVID-19 hospitalized patients categorized by use/non-use of SSRIs on admission and subsequent continuation/discontinuation of SSRIs. Scheme depicts study design, cohort selection, and outcome.
See this image and copyright information in PMC

References

    1. Kuriakose S., Singh K., Pau A.K., Daar E., Gandhi R., Tebas P., Evans L., Gulick R.M., Lane H.C., Masur H., et al. Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Ann. Int. Med. 2021;174:1151–1158. doi: 10.7326/M21-1647. - DOI - PMC - PubMed
    1. Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L., Burgstaller-Muehlbacher S., De Jesus P.D., Teriete P., Hull M.V., et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119. doi: 10.1038/s41586-020-2577-1. - DOI - PMC - PubMed
    1. Xu Y., Chen K., Pan J., Lei Y., Zhang D., Fang L., Tang J., Chen X., Ma Y., Zheng Y., et al. Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease. Int. J. Biol. Macromol. 2021;188:137–146. doi: 10.1016/j.ijbiomac.2021.07.184. - DOI - PMC - PubMed
    1. Chiou W.C., Hsu M.S., Chen Y.T., Yang J.M., Tsay Y.G., Huang H.C., Huang C. Repurposing existing drugs: Identification of SARS-CoV-2 3C-like protease inhibitors. J. Enzym. Inhib. Med. Chem. 2021;36:147–153. doi: 10.1080/14756366.2020.1850710. - DOI - PMC - PubMed
    1. Pickard A., Calverley B.C., Chang J., Garva R., Gago S., Lu Y., Kadler K.E. Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells. PLoS Pathog. 2021;17:e1009840. doi: 10.1371/journal.ppat.1009840. - DOI - PMC - PubMed

LinkOut - more resources